•  
  •  
 

Central Asian Journal of Medicine

Abstract

Introduction. Early diagnosis of sepsis allows to make a diagnosis on time, correctly assess the condition of young children, and start timely treatment. The article analyzes the diagnostic potential of new early marker like procalcitonin. Material and methods. The research involved 82 children with the diagnosis of sepsis, severe sepsis, or septic shock, who were under observation in the Tashkent Medical Academy. The study population constituted all children from newborns to 3 years old patients. All patients were divided into documented bacterial (n=22) versus abacterial inflammation (n=60) infections in order to assess serum PCT concentrations with a cutoff value of >0.5 ng/mL. The traditionally widely used biomarkers of sepsis are cytokines, CRP and PCT. Results and discussion. In the process of sepsis monitoring, procalcitonin unlike other markers, reliably reflects the real dynamics of its severity, quickly and adequately changes depending on the effectiveness of therapy, predicts relapses of sepsis after remission, when the clinical signs of sepsis and procalcitonin levels normalize. With surgical pathology, injuries and burns in the absence of an infection, procalcitonin does not increase. Early diagnosis of sepsis is difficult issue in pediatric practice, whilst it can be vital for positive patient outcomes in sepsis management. Any delay in diagnosis and treatment may bring on multiple organ failure and can be hazardous with elevated mortality consequences. Early diagnosis and effective management of sepsis not only gives an opportunity for prompt antibiotic therapy and a potential decrease in mortality, it can also belittle the unnecessary use of antibiotics. Conclusion. A review of the results of international and domestic studies suggest that procalcitonin is an effective method for the early diagnosis and monitoring of systemic infections of young children.

First Page

190

Last Page

210

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. . The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA (2016) 315:801–10. 2. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med. (2018) 6:223–30. 3. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. (2017) 43:304–77. 10.1007/s00134-017-4683-6 4. Ljungstrom LR, Jacobsson G, Claesson BEB, Andersson R, Enroth H. Respiratory viral infections are underdiagnosed in patients with suspected sepsis. Eur J Clin Microbiol Infect Dis. (2017) 36:1767–76. 10.1007/s10096-017-2990-z 5. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al. . Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. (2015) 191:1147–57. 6. Schlapbach LJ, Straney L, Alexander J, MacLaren G, Festa M, Schibler A, et al. . Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002–13: a multicentre retrospective cohort study. Lancet Infect Dis. (2015) 15:46–54. 7. Ames SG, Workman JK, Olson JA, Korgenski EK, Masotti S, Knackstedt ED, et al. . Infectious etiologies and patient outcomes in pediatric septic shock.J Pediatric Infect Dis Soc. (2017) 6:80–6. 8. Weiss SL, Fitzgerald JC, Balamuth F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 2014; 42: 2409–17. 9. National Institute for Health and Clinical Excellence (NICE). Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection (Clinical Guideline CG149). August 2012. URL: https://www.nice. org.uk/guidance/cg149 (accessed Jan 23, 2017). 10. Van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 2004; 4: 620–30. 11. Vouloumanou EK, Plessa E, Karageorgopoulos DE, Mantadakis E, Falagas ME. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med 2011; 37: 747–62. 12. Chiesa C, Pellegrini G, Panero A, et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003; 49: 60–68. 13. Assumma M, Signore F, Pacifico L, Rossi N, Osborn JF, Chiesa C. Serum procalcitonin concentrations in term delivering mothers and their healthy offspring: a longitudinal study. Clin Chem 2000; 46: 1583–87. 14. Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis 1998; 26: 664–72. 15. De Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16: 819–27. 16. Baer G, Baumann P, Buettcher M, et al. Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. PLoS One 2013; 8: e68419. 17. Centres for Disease Control and Prevention (CDC). CDC 12-step program to prevent antimicrobial resistance in health care settings. April 19, 2002. https://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5115a5.htm (accessed Jan 23, 2017). 18. World Health Organization (WHO). World Health Organization Global Strategy for Containment of Antimicrobial Resistance. 2001. http://www.who.int/drugresistance/WHO_Global_Strategy.htm/ en/ (accessed Jan 23, 2017). 19. Cantey JB, Patel SJ. Antimicrobial stewardship in the NICU. Infect Dis Clin North Am 2014; 28: 247–61. 20. Patel SJ, Rosen E, Zaoutis T, Prasad P, Saiman L. Neonatologists’ perceptions of antimicrobial resistance and stewardship in neonatal intensive care units. Infect Control Hosp Epidemiol 2010; 31: 1298–300. 21. Hersh AL, Beekmann SE, Polgreen PM, Zaoutis TE, Newland JG. Antimicrobial stewardship programs in pediatrics. Infect Control Hosp Epidemiol 2009; 30: 1211–17. 22. Ruppe E, Andremont A. Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria. Front Microbiol 2013; 4: 129. 23. Armand-Lefevre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013; 57: 1488–95 24. Poignant S et al. Risk factors and outcomes for intestinal carriage of AmpC-hyperproducing Enterobacteriadeae in intensive care unit patients. Antimicrob Agents Chemother 2016; 60: 1883–87; 25. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science 2016; 352: 539–44 26. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, M.R. Pinsky, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care., Crit. Care Med. 29 (2001) 1303–10. http://www.ncbi.nlm.nih.gov/pubmed/11445675 (accessed January 18, 2019). 27. L. Bouadma, C.E. Luyt, F. Tubach, C. Cracco, A. Alvarez, C. Schwebel, F. Schortgen, S. Lasocki, B. Veber, M. Dehoux, M. Bernard, B. Pasquet, B. Regnier, C. Brun-Buisson, J. Chastre, M. Wolff, Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial, Lancet. 375 (2010) 463–474. 28. Pierce R, Bigham M, Giuliano JS Jr. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr 2014; 26: 292-8. 29. England JT, Del Vecchio MT, Aronoff SC. Use of serum procalcitonin in evaluation of febrile infants: a meta-analysis of 2317 patients. J Emerg Med 2014; 47:682-8. 30. Yo CH, Hsieh PS, Lee SH, Wu JY, Chang SS, Tasi KC, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children preenting with fever without source. A systematic review and meta-analysis. Ann Emerg Med 2012; 60: 591-600. 31. Vouloumanou EK, Plessa E, Karageorgopoulos DE, Mantadakis E, Falagas ME. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med 2011; 37:747–762. 32. Garcia IJ, Gargallo MB, Torné EE, Lasaosa FJ, Viñas AT, Tolosa CV, et al. Procalcitonin: a useful biomarker to discriminate infection after cardiopulmonary bypass in children. Pediatr Crit Care Med 2012 Jul; 13:441-5. 33. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns 2011; 37:549-58. 34. L. Magrini, G. Gagliano, F. Travaglino, F. Vetrone, R. Marino, P. Cardelli, et al., Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department, Clin. Chem. Lab. Med. 52 (10) (2014 Oct) 1465–1472. 35. D.A. Khan, A. Rahman, F.A. Khan, Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children? J. Clin. Lab. Anal. 24 (1) (2010) 1–5. 36. S. Karlsson, M. Heikkinen, V. Pettila, S. Alila, S. Valissanen, K. Pulkki, et al., Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study, Crit. Care 14 (6) (2010) R205. 37. M.J. Ruiz-Alvarez, S. GarcÃ-a-Valdecasas, R. De Pablo, M.S. GarcÃ-a, C. Coca, T.W. Groeneveld, et al., Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis, J. Intensive Care Med. 24 (1) (2009) 63–71 38. M. Assicot, C. Bohuon, D. Gendrel, J. Raymond, H. Carsin, J. Guilbaud, High serum procalcitonin concentrations in patients with sepsis and infection, Lancet 341 (8844) (1993) 515–518 39. S.D. Carrigan, G. Scott, M. Tabrizian, Toward resolving the challenges of sepsis diagnosis, Clin. Chem. 50 (2004) 1301–1314. 40. M. Stocker, W. Van Herk, S. El Helou, et al., Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns), Lancet 390 (2017) 871–881. 41. C.A. Tamminga, C.B. Nemeroff, R.D. Blakely, L. Brady, C.S. Carter, K.L. Davis, et al., Developing novel treatments for mood disorders: accelerating discovery, Biol. Psychiatry 52 (6) (2002) 589–609. 42. S. Jeong, Y. Park, Y. Cho, H.-S. Kim, Diagnostic utilities of procalcitonin and Creactive protein for the prediction of bacteremia determined by blood culture, Clin. Chim. Acta 413 (21) (2012) 1731–1736. 43. The World Sepsis Declaration. www.worldsepsisday.org, accessed on March 9th, 2019. 44. A. Rhodes, L.E. Evans, W. Alhazzani, et al., Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016, Crit. Care Med. 45 (2017) 486–552. 45. Harvala H, Wolthers KC, Simmonds P. Parechoviruses in children: understanding a new infection. Curr Opin Infect Dis. (2010) 23:224–30. 10.1097/QCO.0b013e32833890ca [PubMed] [CrossRef] [Google Scholar] 46. Hatherill M. Sepsis predisposition in children with human immunodeficiency virus. Pediatr Crit Care Med. (2005) 6(Suppl. 3):S92–8. 10.1097/01.PCC.0000161579.39050.6B [PubMed] [CrossRef] [Google Scholar] 47. Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. Virulence (2014) 5:179–89. 10.4161/viru.27045 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 48. Scheier E, Aviner S. Septicemia following rotavirus gastroenteritis. Isr Med Assoc J. (2013) 15:166–9. [PubMed] [Google Scholar] 49. Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin. (2016) 32:203–12. 10.1016/j.ccc.2015.11.004 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 50. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence (2014) 5:66–72. 10.4161/viru.26907 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 51. Spanuth E., Wilhelm J., Loppnow H. Utility of PATHFAST Presepsin in Septic Patients Admitted to the Emergency Room. 1st Central and Eastern European Sepsis Forum SepsEast Budapest. 2012. 52. Cebreiros-Lopez I., Noguera-Velasco J.A., Martinez-Ruiz A. Correlation od Presepsin (SCD14-ST) with PCT in critically ill patients: Diagnostics usefulness in Sepsis. Euro Med. Lab. 2013 – poster M097. 53. Chenevier-Gobeaux C., Trabattoni E., Roelens M. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values? Clin. Chim. Acta. 2014; 427: 34-6. 54. Spanuth E., Ebelt H., Ivandic B. Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST Presepsin. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011. Poster 0333. 55. Ulla M., Pizzolato E., Lucchiari M. Diagnostic and prognostic value of Presepsin in the management of sepsis in the emergency department: a multicentre prospective study. Crit. Care. 2013; 17(4): R168. 56. Masson S., Caironi P., Spanuth E. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial Crit. Care. 2014, Jan 7; 18(1): R6. 57. Sargentini V., Ceccarelli G., D›Alessandro M. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clin. Chem. Lab. Med. 2014, May 15 58. Spanuth E., Giannitsis E. Diagnosis of sespis and monitoring of weaning from mechanical ventilation in critical ill patients by PATHFAST Presepsin. 20th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine – 19–23 May 2013 – Milano, Italy, T022.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.